GILD•benzinga•
Gilead Sciences: Results From Phase 3 ASCENT-04/KEYNOTE-D19 Study Shows That Trodelvy Plus Keytruda Improved PFS Compared To Keytruda And Chemotherapy In mTNBC Patients
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 21, 2025 by benzinga